EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY
Effect of hyperlipidemia on morbidity and mortality in elderly patients is considered. Authors also cover issues of efficacy and safety of lipid-lowering therapy in primary and secondary prevention of cardiovascular diseases in patients ≥80 years of age who are the most quickly growing group of popu...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-06-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1281 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839641291423481856 |
|---|---|
| author | E. A. Ushkalova O. N. Tkacheva N. K. Runikhina N. A. Chukhareva A. Yu. Bevz |
| author_facet | E. A. Ushkalova O. N. Tkacheva N. K. Runikhina N. A. Chukhareva A. Yu. Bevz |
| author_sort | E. A. Ushkalova |
| collection | DOAJ |
| description | Effect of hyperlipidemia on morbidity and mortality in elderly patients is considered. Authors also cover issues of efficacy and safety of lipid-lowering therapy in primary and secondary prevention of cardiovascular diseases in patients ≥80 years of age who are the most quickly growing group of population and have the highest cardiovascular risk. They stress the need to take into account polymorbidity and polypharmacy that increase the risk of adverse reactions due to the use of both statins and their drug-drug interactions, which requires an assessment of risk/benefit ratio. In addition, there is a need for development of reliable prognostic tools to predict relevant outcomes (e.g., stroke, decrease in functionality/independence, quality of life reduction) and rationales for lipid-lowering therapy in the elderly and also their adherence to treatment. |
| format | Article |
| id | doaj-art-ab5c2077dc1f43b1a67fa55239b1c4b8 |
| institution | Matheson Library |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2016-06-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-ab5c2077dc1f43b1a67fa55239b1c4b82025-07-03T07:28:31ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-06-0112335135810.20996/1819-6446-2016-12-3-351-3581229EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLYE. A. Ushkalova0O. N. Tkacheva1N. K. Runikhina2N. A. Chukhareva3A. Yu. Bevz4Russian University of Peoples' Friendship. Mikluho-Maclaya ul. 6, Moscow, 6117198 RussiaRussian Gerontological Research and Clinical Center. Pervaya Leonova ul. 16, Moscow, 129226 RussiaRussian Gerontological Research and Clinical Center. Pervaya Leonova ul. 16, Moscow, 129226 RussiaScientific Center for Obstetrics, Gynecology and Perinatology named after academician V.I. Kulakov. Oparina ul. 4, Moscow, 117997 RussiaRussian Gerontological Research and Clinical Center. Pervaya Leonova ul. 16, Moscow, 129226 RussiaEffect of hyperlipidemia on morbidity and mortality in elderly patients is considered. Authors also cover issues of efficacy and safety of lipid-lowering therapy in primary and secondary prevention of cardiovascular diseases in patients ≥80 years of age who are the most quickly growing group of population and have the highest cardiovascular risk. They stress the need to take into account polymorbidity and polypharmacy that increase the risk of adverse reactions due to the use of both statins and their drug-drug interactions, which requires an assessment of risk/benefit ratio. In addition, there is a need for development of reliable prognostic tools to predict relevant outcomes (e.g., stroke, decrease in functionality/independence, quality of life reduction) and rationales for lipid-lowering therapy in the elderly and also their adherence to treatment.https://www.rpcardio.online/jour/article/view/1281the elderlyhypercholesterolemialipid-lowering therapy |
| spellingShingle | E. A. Ushkalova O. N. Tkacheva N. K. Runikhina N. A. Chukhareva A. Yu. Bevz EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY Рациональная фармакотерапия в кардиологии the elderly hypercholesterolemia lipid-lowering therapy |
| title | EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY |
| title_full | EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY |
| title_fullStr | EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY |
| title_full_unstemmed | EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY |
| title_short | EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY |
| title_sort | efficacy and safety of lipid lowering drugs in primary and secondary prevention of cardiovascular diseases in the elderly |
| topic | the elderly hypercholesterolemia lipid-lowering therapy |
| url | https://www.rpcardio.online/jour/article/view/1281 |
| work_keys_str_mv | AT eaushkalova efficacyandsafetyoflipidloweringdrugsinprimaryandsecondarypreventionofcardiovasculardiseasesintheelderly AT ontkacheva efficacyandsafetyoflipidloweringdrugsinprimaryandsecondarypreventionofcardiovasculardiseasesintheelderly AT nkrunikhina efficacyandsafetyoflipidloweringdrugsinprimaryandsecondarypreventionofcardiovasculardiseasesintheelderly AT nachukhareva efficacyandsafetyoflipidloweringdrugsinprimaryandsecondarypreventionofcardiovasculardiseasesintheelderly AT ayubevz efficacyandsafetyoflipidloweringdrugsinprimaryandsecondarypreventionofcardiovasculardiseasesintheelderly |